Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT05363111
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
Doctors want to see if a new treatment called 225Ac-DOTA-daratumumab, combined with two other treatments called daratumumab and 111In-DOTA-daratumumab, can help people with multiple myeloma that is hard to treat or has come back. Daratumumab is a special medicine that might stop cancer cells from growing and spreading. The other two treatments have been put together to target cancer cells and might help kill more of them. This is a trial to see if this treatment is safe and if it works well.
Doctors want to see if a new treatment called 225Ac-DOTA-daratumumab, combined with two other treatments called daratumumab and 111In-DOTA-daratumumab, can help people with multiple myeloma that is hard to treat or has come back. Daratumumab is a special medicine that might stop cancer cells from growing and spreading. The other two treatments have been put together to target cancer cells and might help kill more of them. This is a trial to see if this treatment is safe and if it works well.
Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multiple myeloma that does not respond to treatment (refractory) or that has come back (recurrent). Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab are forms of radioimmunotherapy in which a monoclonal antibody, daratumumab, has been linked to a radiotracer to allow for targeted delivery of the treatment to cancer cells. Giving all three together may kill more cancer cells.
This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multiple myeloma that does not respond to treatment (refractory) or that has come back (recurrent). Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab are forms of radioimmunotherapy in which a monoclonal antibody, daratumumab, has been linked to a radiotracer to allow for targeted delivery of the treatment to cancer cells. Giving all three together may kill more cancer cells.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
